Marketing drugs too early in testing.
Publication
, Journal Article
Begg, CB; Brawley, O; Califf, RM; Demets, DL; Ellenberg, SS; Kaplan, RS
Published in: Science
April 14, 2006
Duke Scholars
Published In
Science
DOI
EISSN
1095-9203
Publication Date
April 14, 2006
Volume
312
Issue
5771
Start / End Page
195
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Legislation, Drug
- Humans
- General Science & Technology
- Drug Approval
- Clinical Trials, Phase I as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Begg, C. B., Brawley, O., Califf, R. M., Demets, D. L., Ellenberg, S. S., & Kaplan, R. S. (2006). Marketing drugs too early in testing. Science, 312(5771), 195. https://doi.org/10.1126/science.312.5771.195c
Begg, Colin B., Otis Brawley, Robert M. Califf, David L. Demets, Susan S. Ellenberg, and Richard S. Kaplan. “Marketing drugs too early in testing.” Science 312, no. 5771 (April 14, 2006): 195. https://doi.org/10.1126/science.312.5771.195c.
Begg CB, Brawley O, Califf RM, Demets DL, Ellenberg SS, Kaplan RS. Marketing drugs too early in testing. Science. 2006 Apr 14;312(5771):195.
Begg, Colin B., et al. “Marketing drugs too early in testing.” Science, vol. 312, no. 5771, Apr. 2006, p. 195. Pubmed, doi:10.1126/science.312.5771.195c.
Begg CB, Brawley O, Califf RM, Demets DL, Ellenberg SS, Kaplan RS. Marketing drugs too early in testing. Science. 2006 Apr 14;312(5771):195.
Published In
Science
DOI
EISSN
1095-9203
Publication Date
April 14, 2006
Volume
312
Issue
5771
Start / End Page
195
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Legislation, Drug
- Humans
- General Science & Technology
- Drug Approval
- Clinical Trials, Phase I as Topic